AI R&D Operating System · Life Sciences
From scientific idea to commercially validated product — in one auditable environment.
One shared scientific foundation — target, evidence, molecule, safety, formulation, validation, regulatory, cost, manufacturing — with specialized agents per vertical.
Active projects
5
across 3 verticals
Scientific confidence
74%
portfolio weighted
Lab success rate
68%
last 40 experiments
Formula iterations
33
this quarter
Products by stage
Concept
0
Scientific Validation
1
Candidate Discovery
1
Formula Development
1
Lab Validation
1
Stability
0
Regulatory
1
Pilot Production
0
Commercial Ready
0
Top candidate products
View all| Project | Stage | Sci. conf. | COGS | Margin |
|---|---|---|---|---|
| Lumina Brightening Serum Cosmetics · GCC / Saudi Arabia | Lab Validation | 78% | $3.42 | 61% |
| AXL-Selective Inhibitor Program Pharma · EU / USA | Candidate Discovery | 64% | n/a | — |
| Metabolic Health Complex Supplements · Egypt / GCC | Formula Development | 84% | $1.18 | 68% |
| Metformin XR — Generic Program Pharma · Egypt | Regulatory | 91% | $0.31 | 44% |
| Scalp Renewal Serum Cosmetics · EU | Scientific Validation | 52% | $2.05 | 57% |
Awaiting human approval
High-risk agent findings escalated for scientific review.
- Lumina Brightening Serum
Claim 'removes dark spots' is therapeutic-leaning. Use 'visibly reduces appearance of dark spots'.
- AXL-Selective Inhibitor Program
hERG predicted margin 12× — mandatory patch-clamp before progression.
- Metabolic Health Complex
Berberine × anticoagulant / CYP3A4 interaction — label warning mandatory.
- Scalp Renewal Serum
Classification risk — 'hair growth' wording may trigger medicinal product classification in EU.